Hexarelin GHSR-1a and CD36 Research: GH Secretagogue Receptor Pharmacology

Hexarelin GHSR-1a and CD36 Research: GH Secretagogue Receptor Pharmacology

Hexarelin GHSR-1a and CD36 Research: GH Secretagogue Receptor Pharmacology

Research Overview

Hexarelin represents a synthetic hexapeptide compound extensively investigated in cell-based assay formats for its dual receptor pharmacology profile. This research peptide demonstrates selective agonism at the growth hormone secretagogue receptor type 1a (GHSR-1a) and exhibits ligand activity at the CD36 scavenger receptor. Published in vitro studies characterize its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions. The compound's unique pharmacological profile makes it valuable for investigating receptor-mediated signaling cascades and cellular response mechanisms in cardiovascular and endocrine cell models.

Receptor Pharmacology and Mechanism of Action

GHSR-1a Receptor Interactions

Hexarelin functions as a selective agonist at the GHSR-1a receptor, a G-protein coupled receptor (GPCR) belonging to the ghrelin receptor family. In vitro binding assays demonstrate high affinity interactions with GHSR-1a, exhibiting nanomolar range binding constants in competitive displacement studies. The compound activates Gq/11-mediated signaling pathways, resulting in phospholipase C activation and subsequent inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) generation.

Calcium mobilization assays in GHSR-1a-expressing cell lines reveal robust intracellular calcium release following hexarelin exposure. The peptide demonstrates concentration-dependent receptor activation with EC50 values typically ranging from 10-100 nanomolar in functional assays. Signal transduction studies indicate sustained activation of protein kinase C (PKC) isoforms and downstream effector molecules involved in cellular response regulation.

CD36 Receptor Ligand Activity

Beyond GHSR-1a interactions, hexarelin exhibits binding activity at the CD36 scavenger receptor, a transmembrane glycoprotein involved in lipid recognition and cellular uptake mechanisms. Surface plasmon resonance studies confirm direct binding interactions between hexarelin and CD36 receptor domains. This interaction represents a distinct pharmacological pathway independent of GHSR-1a-mediated effects.

CD36 binding assays demonstrate moderate affinity interactions, with dissociation constants in the micromolar range. The compound's interaction with CD36 receptors triggers alternative signaling cascades involving src-family kinases and focal adhesion kinase (FAK) phosphorylation pathways.

Signaling Pathway Analysis

PI3K/AKT Pathway Activation

Hexarelin treatment in cell culture models consistently activates the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway. Western blot analysis reveals time-dependent phosphorylation of AKT at both Ser473 and Thr308 residues following peptide exposure. This activation occurs through both GHSR-1a-dependent and CD36-mediated mechanisms, suggesting convergent signaling pathway regulation.

Pathway inhibitor studies using specific PI3K antagonists demonstrate reduced AKT phosphorylation, confirming the involvement of PI3K upstream signaling. Downstream targets of AKT activation include glycogen synthase kinase-3β (GSK-3β) and mammalian target of rapamycin (mTOR), which exhibit increased phosphorylation status in hexarelin-treated cell cultures.

MAPK Cascade Engagement

Mitogen-activated protein kinase (MAPK) pathway analysis reveals hexarelin-induced activation of extracellular signal-regulated kinases (ERK1/2). Immunoblotting studies demonstrate phosphorylation of ERK1/2 within 15-30 minutes of peptide exposure in various cell models. This activation appears primarily mediated through GHSR-1a receptor engagement and subsequent PKC-dependent signaling.

Cardiovascular Cell Model Applications

Cardiomyocyte Culture Studies

Primary cardiomyocyte cultures provide valuable models for investigating hexarelin's cardiac-specific receptor pharmacology. These cell systems express both GHSR-1a and CD36 receptors, enabling comprehensive analysis of the compound's dual receptor targeting effects. Contractility assays in cultured cardiomyocytes demonstrate enhanced calcium handling and improved cellular viability parameters following hexarelin treatment.

Endothelial Cell Investigations

Human umbilical vein endothelial cell (HUVEC) models reveal hexarelin's effects on vascular cell function through CD36 and GHSR-1a receptor interactions. Angiogenesis assays, including tube formation and migration studies, demonstrate enhanced endothelial cell responses in the presence of hexarelin. These effects correlate with increased nitric oxide production and improved endothelial barrier function in cell culture systems.

Enzyme Kinetics and Binding Affinity Studies

Detailed pharmacokinetic analysis reveals hexarelin's binding characteristics across multiple receptor targets. Scatchard plot analysis indicates single-site binding at GHSR-1a receptors with Kd values ranging from 5-50 nanomolar depending on cell model systems. CD36 binding exhibits lower affinity but demonstrates significant biological activity at micromolar concentrations.

Competition binding studies using radiolabeled hexarelin confirm receptor selectivity profiles and identify potential allosteric binding sites. These investigations provide crucial data for understanding structure-activity relationships and optimizing experimental protocols for cell-based assays.

Research Summary

Hexarelin demonstrates complex receptor pharmacology through dual targeting of GHSR-1a and CD36 receptors in cell culture models. The compound activates multiple signaling pathways including PI3K/AKT and MAPK cascades, providing valuable tools for investigating receptor-mediated cellular responses. Its applications in cardiovascular cell models offer insights into receptor biology and signaling mechanism research, making it a useful compound for in vitro pharmacological investigations.

All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.

Hexarelin

TB-500

Epithalon

Ipamorelin

Tirzepatide

CJC-1295 DAC

PT-141

Semaglutide

Selank

BPC-157

Sermorelin

Melanotan 2

IGF LR3

Tesamorelin

AICAR

IGF-DES

GHRP 2

Albuterol

Tamoxifen

Letrozole

Clomiphene

Tadalafil

Clenbuterol

Anastrozole

Finasteride

Exemestane

Sildenafil

Yohimbine

Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows

Already a customer? Sign In

Create Account

All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.

ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.

Sarms

Stacks

Research Liquids

Albuterol 5MG/ML | 30ML with dropper

Anastrozole 1.5MG/ML | 30ML with dropper

Clomiphene 50MG/ML | 30ML with dropper

Finasteride 5MG/ML | 30ML with dropper

Letrozole 3.5 MG/ML | 30ML with dropper

LiquiCia 30MG/ML | 30ML with dropper

LiquiCia T50 50MG/ML | 30ML with dropper

LiquiClen 200MCG/ML | 30ML with dropper

Liquistane / Exemestane 25MG/ML | 30ML with dropper

LiquiTamo 20MG/ML | 30ML with dropper

LiquiVia 25MG/ML | 30 ML with dropper

T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper

Toremifene Citrate 60MG/ML | 30ML with dropper

Yohimbine HCL 10MG/ML | 30ML with dropper

Research Peptides

Aicar 50MG

BPC-157 + TB-500 Blend 2mg ea/ 4MG

BPC-157 5MG

CJC-1295 + DAC 2MG

CJC-1295 | No DAC 2MG

Epithalon 10MG

Frag Premium 176-191 5MG

GHK-CU Copper Peptide 50MG

GHRP-2 5MG

GHRP-6 5MG

Hexarelin 5MG

IGF-1 DES 1MG

IGF-1 LR3 1MG

Ipamorelin 5MG

Melanotan 2 10MG

NAD+ 500MG

PT-141 / Bremelanotide 10MG

GLP-1/GIP/GCG (RT)

Selank 5MG

GLP1 (SM)

Sermorelin 5MG

TB-500 5MG

GIP/GLP-1 (TZ)

PDE5 Inhibitors

GLP-1

Diluents

Bacteriostatic Water 10ML